Ms. Whitaker has been a director since May 2018 and is a member of Mallinckrodt’s Human Resources and Compensation Committee.
She has been a director of Cree Inc. and member of its Compensation Committee since 2013. Previously she served as a director on the board of Synta Pharmaceuticals Corp. from 2014 to 2015.
Ms. Whitaker has held the role of chief executive officer for KNOW Bio, LLC and Novoclem Therapeutics, Inc., a wholly owned subsidiary of KNOW Bio since 2017. Previously with Valeant Pharmaceuticals from 2015 to 2017, Ms. Whitaker served as executive vice president and company group chairman with responsibility for the company’s branded pharmaceutical segment including key businesses like Salix, Dendreon, and Orapharma as well as the Canadian and Western Europe regions. Prior to that she served as president and chief executive officer at Synta Pharmaceuticals Corp. from 2014 to 2015; as president of North America pharmaceuticals and consumer health at Sanofi S.A. from 2011-2014; and in various roles at GSK, most recently as senior vice president and business unit head of the Cardiovascular, Metabolic and Urology Division.
Ms. Whitaker received a bachelor of science in chemistry from the University of North Alabama.